Compare · BRKR vs CTKB
BRKR vs CTKB
Side-by-side comparison of Bruker Corporation (BRKR) and Cytek Biosciences Inc. (CTKB): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both BRKR and CTKB operate in Biotechnology: Laboratory Analytical Instruments (Industrials), so they compete in similar markets.
- BRKR is the larger of the two at $8.40B, about 16.4x CTKB ($511.4M).
- Over the past year, BRKR is up 38.1% and CTKB is up 20.1% - BRKR leads by 18.0 points.
- CTKB has been more active in the news (12 items in the past 4 weeks vs 8 for BRKR).
- BRKR has more recent analyst coverage (22 ratings vs 13 for CTKB).
- Company
- Bruker Corporation
- Cytek Biosciences Inc.
- Price
- $54.16-0.11%
- $3.96-0.13%
- Market cap
- $8.40B
- $511.4M
- 1M return
- +22.21%
- +17.91%
- 1Y return
- +38.06%
- +20.06%
- Industry
- Biotechnology: Laboratory Analytical Instruments
- Biotechnology: Laboratory Analytical Instruments
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2021
- News (4w)
- 8
- 12
- Recent ratings
- 22
- 13
Bruker Corporation
Bruker Corporation develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates through three segments: Bruker Scientific Instruments (BSI) Life Science, BSI NANO, and Bruker Energy & Supercon Technologies. It offers life science tools based on magnetic resonance technology; life science mass spectrometry and ion mobility spectrometry solutions; analytical and process analysis instruments and solutions based on infrared and Raman molecular spectroscopy technologies; and radiological/nuclear detectors for chemical, biological, radiological, nuclear, and explosive detection. The company also provides X-ray instruments, atomic force microscopy instrumentation, fluorescence optical microscopy instruments, analytical tools for electron microscopes and X-ray metrology, defect-detection equipment for semiconductor process control, and spark optical emission spectroscopy systems, as well as handheld, portable, and mobile X-ray fluorescence spectrometry instruments. In addition, it offers superconducting and non-superconducting materials and devices. The company serves academic and government research customers; pharmaceutical and biotechnology, diagnostics, chemical, food and beverage, clinical, nanotechnology, semiconductor, and other industrial companies; nonprofit laboratories; academic institutions and medical schools; contract research organizations; nonprofit and for-profit forensics, and environmental and clinical microbiology laboratories; agriculture, food, and beverage safety laboratories; hospitals and government departments; agencies; raw material manufacturers; and other businesses involved in materials analysis through direct sales forces, distributors, independent sales representatives, and other representatives. Bruker Corporation was incorporated in 1991 and is headquartered in Billerica, Massachusetts.
Latest BRKR
- SEC Form S-3ASR filed by Bruker Corporation
- Bruker Showcases Expanding Microbiology & Infection Diagnostics Portfolio at ASM Microbe 2026
- Bruker Launches new timsMRMS Mass Spectrometry Platform for Unique Ultra-Complex Mixture Applications in the Energy Industry
- Wolfe Research resumed coverage on Bruker
- Bruker Announces Major Strides in 4D Proteomics Performance, Further Advances In Intact and Top-Down Functional Proteoform Analysis, and Innovations in Hybrid Qual/Quant 4D Metabolomics – all to Enable Deeper Insights into Disease Biology
- SEC Form SD filed by Bruker Corporation
- Amendment: Bruker Corporation filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders
- Champalimaud Foundation's Neuroscience and Oncology Research Benefits from 18 Tesla Ultra-High Field MRI
- Bruker Corporation filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders
- Director Bernard Thierry was granted 2,886 shares (SEC Form 4)
Latest CTKB
- Director Ball Jack converted options into 43,973 shares, increasing direct ownership by 103% to 86,678 units (SEC Form 4)
- SEC Form 4 filed by Director Muir Glenn P
- SEC Form 3 filed by new insider Muir Glenn P
- SEC Form 4 filed by Director Chin Richard
- Director Imper Vera converted options into 43,973 shares, increasing direct ownership by 280% to 59,679 units (SEC Form 4)
- Director Neff Deborah J converted options into 43,973 shares, increasing direct ownership by 280% to 59,679 units (SEC Form 4)
- Director Holder Michael converted options into 43,973 shares, increasing direct ownership by 263% to 60,694 units (SEC Form 4)
- Cytek Biosciences to participate at the Singular Research's Las Vegas Invitational Conference
- Marvell Technology and Flex Set to Join S&P 500; Others to Join S&P MidCap 400 and S&P SmallCap 600
- Cytek Biosciences to Unveil Next-Generation Spectral Flow Cytometry Innovations at CYTO 2026